OasisLMS

The relationship between childhood adversities and obesogenic behaviors is complex, yet the pathways underlying susceptibility to obesity in individuals with a history of childhood adversity remain elusive. Dr. Figueroa will share the latest discoveries from his laboratory, revealing how early adversities reshape the gut microbiome-brain axis to influence behavior and obesity risk.

1. After participating in the webinar, learners will be able to describe evidence-based science regarding environmental, microbiota, neuroendocrine, and neurobiological mechanisms influencing obesogenic behaviors in stressful conditions.

2. After participating in the webinar, learners will be able to identify new therapeutic targets that may influence stress-induced obesogenic behaviors.

3. After this webinar, learners will be able to formulate and execute preventive and therapeutic strategies aimed at decreasing obesity among individuals at risk.

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACCME Activity ID 202573203

Date of Release: May 1, 2024
Date of Termination: December 31, 2026

No commercial support was received for this activity.

Johnny Figueroa, PhD: No Relevant Financial Relationships

Monica Agarwal, MD: No Relevant Financial Relationships

Johnny Figueroa, PhD: No Relevant Financial Relationships

Leslie Golden, MD, MPH: No Relevant Financial Relationships

Valentina Ivezaj, PhD: No Relevant Financial Relationships

Aaron Kelly, PhD: No Relevant Financial Relationships

Robert Kushner, MD: Advisor Relationship with Novo Nordisk (Pharmaceuticals), WW (Medical Food and Weight Management*), and Eli Lilly (Pharmaceuticals) Consultant relationship with Altimmune (Pharmaceuticals), Pfizer Inc. (Pharmaceuticals), and Boehringer Ingelheim (Pharmaceuticals)

Magdalena Pasarica, MD, PhD: No Relevant Financial Relationships Jonathan Purnell, MD Consultation Relationship with Novo Nordisk (Pharmaceuticals), Boehringer Ingelheim (Pharmaceuticals), and Luciole (Pharmaceuticals)

Amanda Velazquez, MD: Advisor relationship with WW (Medical Food and Weight Management*) and Intellihealth (Weight Management*) Consultation Relationship with Novo Nordisk (Pharmaceuticals)

Denise Wilfley, PhD: No Relevant Financial Relationships

No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

1. Sharafeddin F, Ghaly M, Simon TB, Ontiveros-Ángel P, Figueroa JD. Prefrontal cortical protease TACE/ADAM17 is involved in neuroinflammation and stress-related eating alterations. bioRxiv [Preprint]. 2023 Jan 24:2023.01.23.525269. doi: 10.1101/2023.01.23.525269.
2. Vega-Torres JD, Azadian M, Rios-Orsini RA, et al. Adolescent Vulnerability to Heightened Emotional Reactivity and Anxiety After Brief Exposure to an Obesogenic Diet. Front Neurosci. 2020 Jun 30;14:562. doi: 10.3389/fnins.2020.00562.
3. Vega-Torres JD, Ontiveros-Angel P, Terrones E, et al. Short-term exposure to an obesogenic diet during adolescence elicits anxiety-related behavior and neuroinflammation: modulatory effects of exogenous neuregulin-1.Transl Psychiatry. 2022 Feb 26;12(1):83. doi: 10.1038/s41398-022-01788-2.
4. Vega-Torres JD, Haddad E, Lee JB, et al. Exposure to an obesogenic diet during adolescence leads to abnormal maturation of neural and behavioral substrates underpinning fear and anxiety. Brain Behav Immun. 2018 May;70:96-
117. doi: 10.1016/j.bbi.2018.01.011.